Current Report Filing (8-k)
July 27 2017 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 26, 2017
Infinity Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware
|
|
000-31141
|
|
33-0655706
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
784 Memorial Drive, Cambridge, MA
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617) 453-1000
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item 1.01
|
Entry into a Material Definitive Agreement
|
On July 26, 2017, Infinity
Pharmaceuticals, Inc. (the Company, we, or our) entered into a third amendment (the Third Amendment) to our Amended and Restated Development and License Agreement with Intellikine LLC
(Intellikine and such agreement, as amended, the Intellikine Agreement). Intellikine was subsequently acquired by Takeda Pharmaceuticals Company Limited acting through its Millennium business unit. Under the Third Amendment,
our obligations to Intellikine under the Intellikine Agreement to pay royalties with respect to worldwide net sales of products containing or comprised of a selective inhibitor of
phosphoinositide-3-kinase
(PI3K) gamma, including but not limited to
IPI-549,
are terminated. In consideration for
such termination, we concurrently executed a convertible promissory note (the Note) pursuant to which we are obligated to pay Intellikine, or its designated affiliate, the principal amount of $6,000,000 together with interest accruing at
a rate of 8% per annum on or before July 26, 2018 in cash or in shares of Company common stock, at the election of Intellikine. The share payment price would be equal to the average closing price of Company common stock for the 20 days prior to
the payment date. We have the right to prepay the Note, in whole or in part, without penalty and any amounts owed under the Note would become immediately due and payable in the event of a change of control of the Company, as defined in the Note.
Additionally, any unpaid amounts may become immediately due and payable upon customary events of default, as defined in the Note.
In the
event that Intellikine elects to receive one or more payments in shares of Company common stock (a Share Repayment), we have agreed to file one or more registration statements on Form
S-3
with the
Securities and Exchange Commission (SEC) to register for resales the shares of common stock issuable upon repayment of the Note (Repayment Shares) within 45 days after each Share Repayment. In the event that we propose to
make an underwritten offering of our common stock, subject to certain limitations, Intellikine will have piggyback registration rights, which require us, at the election of Intellikine, to cause to be included in such underwritten
offering, any Repayment Shares then held by Intellikine.
The foregoing descriptions of the Third Amendment and Note do not purport to be
complete and are qualified in their entirety by reference to the complete text of the Third Amendment and Note, which we intend to file with the SEC as exhibits to our Quarterly Report on Form
10-Q
for the
period ending September 30, 2017.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an
Off-Balance
Sheet Arrangement of a Registrant
The information provided in Item 1.01 relating to the
Note is hereby incorporated by reference into this Item 2.03.
Item 3.02
|
Unregistered Sales of Equity Securities
|
The information provided in Item 1.01 relating
to the Note is hereby incorporated by reference into this Item 3.02. The Note described in Item 1.01 above was offered and sold in reliance upon exemptions from registration pursuant to Section 4(a)(2) under the Securities Act of 1933
(Securities Act). Such reliance was based upon Intellikines representation that it is an accredited investor as defined in Rule 501(a) under the Securities Act.
Item 9.01
|
Financial Statements and Exhibits
|
(d) The following exhibit is included in this report:
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated July 27, 2017
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
INFINITY PHARMACEUTICALS, INC.
|
|
|
|
|
Date: July 27, 2017
|
|
|
|
By:
|
|
/s/ Seth A. Tasker
|
|
|
|
|
|
|
Seth A. Tasker
|
|
|
|
|
|
|
VP, General Counsel
|
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Apr 2023 to Apr 2024